Physicians involved in clinical trials should have the patient in mind “from the very conception of the design to the conduct of the study to dissemination of the results,” says Angela B. Smith, MD, MS.
In this video, Angela B. Smith, MD, MS, discusses how to ensure a clinical trial is patient centered. Smith presented a talk on the subject at the 2020 Society of Urologic Oncology Annual Meeting. Smith is vice chair of academic affairs, director of urologic oncology, and associate professor of urology at UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.